Interplays Between Non-Coding Rnas and Chemokines in Digestive System Cancers Publisher Pubmed



Jafarzadeh A^{1, 2, 3} ; Seyedmoalemi S^{4, 5} ; Dashti A⁶ ; Nemati M^{7, 8} ; Jafarzadeh S⁹ ; Aminizadeh N¹⁰ ; Vosough M¹¹ ; Rajabi A^{12, 13} ; Afrasiabi A¹⁴ ; Mirzaei H¹⁵ Show Affiliations
Source: Biomedicine and Pharmacotherapy Published:2022

Abstract

Within tumors, chemokines and their cognate receptors are expressed by infiltrated leukocytes, cancerous cells, and related cells of stroma, like tumor-associated fibroblasts and tumor-associated macrophages. In malignancies, the altered expression of chemokines/chemokine receptors governs leukocyte infiltration and activation, epithelial-mesenchymal transition (EMT), cancer cell proliferation, angiogenesis, and metastasis. Non-coding RNAs (ncRNAs) contribute to multiple physiological and pathophysiological processes. Some miRNAs can exert anti-tumorigenic activity in digestive system malignancies by repressing the expression of tumor-promoting chemokines/chemokine receptors or by upregulating tumor-suppressing chemokines/chemokine receptors. However, many miRNAs exert pro-tumorigenic activity by suppressing the expression of chemokines/chemokine receptors or by upregulating tumor-promoting chemokines/chemokine receptors. LncRNA and circRNAs also exert pro- and anti-tumorigenic effects by targeting downstream miRNAs influencing the expression of tumor-promoting and tumor-suppressor chemokines/chemokine receptors. On the other side, some chemokines influence the expression of ncRNAs affecting tumor formation. The current review explains the communications between ncRNAs and chemokines/chemokine receptors in certain digestive system malignancies, such as gastric, colorectal, and pancreatic cancers and hepatocellular carcinoma to gain better insights into their basic crosstalk as well as possible therapeutic modalities. © 2022 The Authors